CompuMed to acquire Northeast Imaging
CompuMed of Manhattan Beach, CA, announced this month its intention to acquire the assets of Northeast Imaging Center of East Orange, NJ. The deal will increase CompuMed's revenues by about 50% and will give the firm access to a medical imaging operation
CompuMed of Manhattan Beach, CA, announced this month its intention to acquire the assets of Northeast Imaging Center of East Orange, NJ. The deal will increase CompuMed's revenues by about 50% and will give the firm access to a medical imaging operation in which it could potentially use its products. Northeast Imaging's medical imaging center supplies outpatient care and brings in annual revenues of approximately $1 million. According to CompuMed executives, there will be no personnel changes, but administrative operations will be centralized.
CompuMed's products and services include the developmental Digital OsteoView 2000, a bone-density and arthritis testing device, the OsteoGram bone-density testing software, telemedicine services for cardiology, and online computer interpretation of electrocardiograms. Despite the company's R&D activities, it has had difficulty building a solid revenue stream: The company estimates its 1997 sales at $1.75 million.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
